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Changes in DNA methylation frequently accompany cancer development. One prominent
change is an apparently genome-wide decrease in methylcytosine that is often ascribed
to DNA hypomethylation at retroelements comprising nearly half the genome. DNA
hypomethylation may allow reactivation of retroelements, enabling retrotransposition, and
causing gene expression disturbances favoring tumor development. However, neither the
extent of hypomethylation nor of retroelement reactivation are precisely known. We there-
fore assessed DNA methylation and expression of three major classes of retroelements
(LINE-1, HERV-K, and AluY ) in human urinary bladder cancer tissues and cell lines by
pyrosequencing and quantitative reverse transcription–polymerase chain reaction, respec-
tively. We found substantial global LINE-1 DNA hypomethylation in bladder cancer going
along with a shift toward full-length LINE-1 expression. Thus, pronounced differences in
LINE-1 expression were observed, which may be promoted, among others, by LINE-1
hypomethylation. Significant DNA hypomethylation was found at the HERV-K_22q11.23
proviral long terminal repeat (LTR) in bladder cancer tissues but without reactivation of its
expression. DNA methylation of HERVK17, essentially absent from normal urothelial cells,
was elevated in cell lines from invasive bladder cancers. Accordingly, the faint expression
of HERVK17 in normal urothelial cells disappeared in such cancer cell lines. Of 16 addi-
tional HERV-Ks, expression of 7 could be detected in the bladder, albeit generally at low
levels. Unlike in prostate cancers, none of these showed significant expression changes
in bladder cancer. In contrast, expression of the AluYb8 but not of the AluYa5 family was
significantly increased in bladder cancer tissues. Collectively, our findings demonstrate a
remarkable specificity of changes in expression and DNA methylation of retroelements in
bladder cancer with a significantly different pattern from that in prostate cancer.
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INTRODUCTION
Human cancers are marked by several genetic and epigenetic
changes. In particular, it is well established that aberrant DNA
methylation contributes to cancer development. At specific loci,
DNA hypermethylation in combination with the gain of a repres-
sive chromatin conformation leads to gene silencing (1). Notably,
whereas hypermethylation often targets genes already weakly tran-
scribed in normal tissues, some epigenetically repressed genes exert
tumor suppressive functions and their silencing by hypermethyla-
tion contributes to tumor development (2). In contrast to hyper-
methylation affecting single genes or selected genomic regions,
a global decrease of methylcytosine occurs in cancers (3, 4). In
benign tissues the bulk of the genome is densely DNA methylated.
This methylation is believed to be one mechanism of restrain-
ing the activity of retroelements that comprise nearly half of the
human genome (5). As several retroelements have retained their
ability to retrotranspose, hypomethylation was proposed to enable
their reactivation and thereby to contribute to the destabilization
of the genome in cancer cells (4, 6). Global hypomethylation has
been observed in many cancers, albeit occurring at different stages
and to varying extents depending on the tumor entity (3).
For instance, many prostate cancers exhibit only a minor
decrease in LINE-1 promoter methylation (7) with hypomethy-
lation aggravating in higher stage carcinomas (8). Conversely,
urothelial carcinoma of the urinary bladder was reported to
show a higher decrease of LINE-1 methylation which was preva-
lent across all tumor stages (9–11). Likewise, hypomethylation of
HERV-K retroelements was observed in bladder cancer cell lines
and tissues correlating well with the decline of LINE-1 methy-
lation (9). However, activation of HERV-K elements was not
found in that study. In prostate cancers one specific HERV-K
element, referred to as HERV-K_22q11.23 (H22q) was strikingly
upregulated in cancerous tissues and this overexpression corre-
lated well with hypomethylation of its long terminal repeat (LTR)
(7). Remarkably, mRNA expression of the H22q provirus has
been reported in several tumor entities and antibodies against
H22q Gag protein have been detected in sera from bladder,
liver, lung, ovarian, and prostate cancer patients (12). Interest-
ingly, the androgen-responsive LTRs of H22q and HERVK17 are
involved in translocation events with ETV1, a member of the
ETS family of transcription factors (13, 14). These events rep-
resent rare variants of the common translocations in prostate
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cancer that lead to oncogenic activation of ETS transcription
factors.
While the above findings have highlighted the potential role
of HERV-K proviruses in prostate carcinogenesis, reports con-
cerning HERV-K expression in bladder cancer remain sporadic.
By using massively parallel signature sequencing (MPSS) Stauffer
et al. (15) detected HERV-K expression in normal bladder tissue
resulting from a subgroup of 17 HERV-K elements. Of particular
interest might be the expression of the melanoma-associated anti-
gen HERV-K-MEL in a subset of bladder cancers (16). We have
now conducted a broader and detailed analysis of retroelement
DNA methylation and expression changes in urothelial carcino-
mas using mainly established quantitative pyrosequencing and
quantitative reverse transcription PCR (qRT-PCR) methods previ-
ously applied to prostate cancer. This allows a direct comparison of
methylation and expression changes between these genitourinary
cancer entities.
MATERIALS AND METHODS
TISSUE SAMPLES AND CELL LINES
Patients and tumor characteristics are compiled in Table 1. Patient
consent was obtained and the study approved by the Ethics
Committee of the Medical Faculty of the Heinrich Heine Uni-
versity. All urothelial cancer cell lines (253J, 5637, 639-V, 647-
V, BFTC-905, HT-1376, J82, MGH-U4, RT4, RT-112, SCaBER,
SD, SW1710, UMUC3, UMUC6, VMCUB1, T24) and cancer-
associated fibroblasts were cultured in DMEM GlutaMax (Gibco,
Darmstadt, Germany), supplemented with 10% fetal calf serum
as described previously using standard methods (17). The cell
lines were obtained from the DSMZ (Braunschweig, Germany),
except UMUC3, kindly provided by Dr. Grossman, Houston.
The telomerase-immortalized TERT-NHUC cell line was kindly
provided by Prof. M. A. Knowles (Leeds, UK) and cultured
as described previously (18). The well-differentiated urothelial
carcinoma cell line BC61 established in our lab was cultured
as described (19). Primary urothelial cells cultures (UP) were
established from ureters after nephrectomy and were routinely
maintained in keratinocyte serum-free medium (KSFM, Gibco,
Darmstadt, Germany) supplemented with 12.5µg/ml bovine pitu-
itary extract and 0.25 ng/ml epidermal growth factor as described
previously (20).
Nucleic acids extraction and quantitative reverse
transcription–polymerase chain reaction
High molecular weight DNA and total RNA were extracted from
powdered tissues using standard protocols. Notably, RNA extrac-
tion involved acid phenol extraction followed by column purifica-
tion to minimize DNA contamination. Further DNA contamina-
tion was removed by synthesis of complementary DNA including
a DNA removal step by DNase using the QuantiTect Reverse
Transcription Kit (Qiagen, Hilden, Germany), according to the
manufacturer’s protocol. In order to estimate the remaining lev-
els of genomic DNA after cDNA preparation, amplification values
for three different retroelement specific qPCR assays (HERVK17,
LINE-1_5′ and LINE-1_3′) were assessed by quantitative PCR
using cDNA preparations from three different bladder cancer cell
lines (5637, BC61 and RT4) with or without reverse transcriptase
Table 1 | Clinical characterization of tissue sample sets.
DNA set
(n=23)
RNA set
(n=24)
Age Median 65 66
95% CI 61–71 63–69
Range 41–84 45–84
Gender, n (%) Female 7 (30.4) 5 (20.8)
Male 16 (69.6) 19 (79.2)
Pathological T stage, n (%) pTa 3 (13.0) 1 (4.2)
pT1 1 (4.3) 0 (0)
T2 4 (17.4) 7 (29.2)
T3 10 (43.5) 11 (45.8)
T4 5 (21.7) 5 (20.8)
Nodal status, n (%) Negative 11 (47.8) 13 (54.2)
Positive 7 (30.4) 8 (33.3)
Unknown 5 (21.7) 3 (12.5)
Tumor grading, n (%) G1 1 (4.3) 0 (0)
G2 5 (21.7) 7 (29.2)
G3 17 (73.9) 17 (70.8)
(RT) treatment after DNA removal. As shown in Figure 1B
(inset), amplification levels of background genomic DNA were
at most around 1% of the total expression of high-copy retroele-
ments (LINE-1_5′ and LINE-1_3′). With an assay for single-copy
retroelement (HERVK17 ) amplification from genomic DNA was
essential absent (cf. Figure 1B).
Quantitative reverse transcription (qRT)–PCR was performed
as described previously (7) on a 7500 Fast Real-Time PCR Sys-
tem (Applied Biosystems, Carlsbad, CA, USA) using QuantiTect
SYBR Green PCR Kit (Qiagen). Initial qualitative PCR with spe-
cific primers listed in Table 2 was performed as following: initial
denaturation step at 95°C for 15 min, followed by 35 amplifica-
tion cycles consisting of denaturation at 94°C for 15 s, annealing
at 56°C for 15 s, and extension at 72°C for 30 s. Samples were ana-
lyzed on 1.5% agarose gels. Assays with detectable transcripts in
this qualitative PCR were subjected to quantitative PCR analy-
sis. All qRT-PCR data were adjusted to TATA-box-binding protein
(TBP) mRNA measured by a specific TBP assay (Table 2). For
all other transcripts, specifically designed primers (Table 2) were
employed using the following PCR conditions: initial denatura-
tion step at 95°C for 15 min, followed by 40 amplification cycles
consisting of denaturation at 95°C for 15 s, annealing for 20 s, and
extension at 72°C for 30 s. All measurements were performed in at
least duplicates; assay variance was<10%. Relative expression was
calculated by a modified ∆∆Ct method published by Pfaffl (21).
BISULFITE TREATMENT AND DNA METHYLATION ANALYSES
Bisulfite conversion was performed using the EZ DNA
Methylation-Gold Kit (Zymo Research,Hiss Diagnostics,Freiburg,
Germany) according to the manufacturer’s instructions. Bisulfite-
treated DNA samples were used for PCR with the indicated
primers (Table 2) using HotStartTaq (Qiagen) under the following
conditions: initial denaturation step at 95°C for 15 min, followed
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FIGURE 1 | DNA methylation and expression changes of LINE-1 elements
in bladder cancer. (A) DNA methylation in the CpG islets of LINE-1 was
quantified by pyrosequencing in a set of 10 normal urothelial cell cultures and
18 bladder cancer cell lines. For comparison, LINE-1 DNA methylation was
assessed in immortalized urothelial cells (TERT-NHUC) and in uncultured
epithelial cells (uncultured UP) and connective tissue from one ureter.
(B) LINE-1 RNA levels from the 5′- and 3′-regions were measured by qRT-PCR
in a set of 6 normal urothelial cell cultures and 18 bladder cancer cell lines.
Inset: amplification of different retroelements (HERVK17, LINE-1_5 ′ and
LINE-1_3 ′) was measured in three bladder cancer cell lines using cDNA
preparations with (+) or without (−) reverse transcriptase (RT) to assess the
impact of genomic DNA contamination. Results were adjusted for each assay
and cell line to reverse transcriptase positive preparations set as 100%
(C) LINE-1 DNA methylation and expression of the 5′- and 3′-regions were
analyzed in a set of 12 benign and 23 cancerous bladder tissues or 11 benign
and 24 tumorous bladder tissues, respectively. Methylation is plotted as mean
methylation value from four CpGs in percent (A,C). RNA levels were each
normalized to TBP and standardized to either the median RNA level of normal
urothelial cell cultures (B) or the median RNA level of benign bladder tissues
(C) set as 1. p Values calculated by the Mann–Whitney U -test were given
above the brackets for significant changes (p<0.05). Missing p values
demonstrate changes without reaching the level of significance.
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Table 2 | Oligonucleotides.
Gene/region Sequence Bases (NCBI/hg19) Primer Sequence 5′–3′
HERV-K_3p25.3 Chromosome 3 9,895,774–9,895,791 H3p25_for GCATCTGTCTCCTGCTTG
HERV-K_3p25.3 Chromosome 3 9,895,722–9,895,740 H3p25_rev ATCTCAGTAGATGGAATCG
HERV-K_3q12.3 Chromosome 3 101,411,166–101,411,184 H3q12_for GTGCTGAGGAGGATTAGTG
HERV-K_3q12.3 Chromosome 3 101,411,341–101,411,358 H3q12_rev AGTATTGCTGCCGGCTTG
HERV-K_3q21.2 Chromosome 3 125,609,734–125,609,755 H3q21_for ATTAGTAAAAGAGGAAAGAATG
HERV-K_3q21.2 Chromosome 3 125,609,821-125,609,842 H3q21_rev CATACAATCAGGTTTTATACTG
HERV-K_3q27.2 Chromosome 3 185,288,247–185,288,266 H3q27_for CATGGTTTCCAGAACAAGAA
HERV-K_3q27.2 Chromosome 3 185,288,095–185,288,116 H3q27_rev GAAACTGAAACGCTATCTTCTG
HERV-K_10p14 Chromosome 10 6,875,319–6,875,337 H10p14_for CTCAACTACCCAGGGATAC
HERV-K_10p14 Chromosome 10 6,875,183–6,875,200 H10p14_rev TTACGGGTGTCGAGCTGC
HERV-K_11q22.1 Chromosome 11 101,572,720–101,572,739 H11q22_for TCCTATTTGCTTAGGGACAG
HERV-K_11q22.1 Chromosome 11 101,572,768–101,572,787 H11q22_rev GTACTTCTACCAACCAGTTT
HERV-K_12q14.1 Chromosome 12 58,730,155–58,730,176 H12q14_for TGTCTCGGTATAAAACCTGACT
HERV-K_12q14.1 Chromosome 12 58,729,973–58,729,993 H12q14_rev GTCAGCAGACAAACATGTGAA
HERV-K_12q24.11 Chromosome 12 111,008,880–111,008,897 H12q24_for GACGAGAGATCCCGAGGA
HERV-K_12q24.11 Chromosome 12 111,008,929–111,008,947 H12q24_rev CCCTAGCTTCTTCCGAGTG
HERV-K_10 Chromosome 5 156,085,657–156,085,678 H10_for GAAAAGCAAGAGAGATCAAATT
HERV-K_10 Chromosome 5 156,085,583–156,085,603 H10_rev GCAGAAGAATTTTTCTTAGCA
HERV-K_18.2 Chromosome 1 160,661,401–160,661,422 H18_for ATCCTCCATATGCTGAACGTTG
HERV-K_18.2 Chromosome 1 160,661,489–160,661,510 H18_rev TGTTTCTCGTAAGGTGCAATGA
HERV-K_102 AF164610.1 (NCBI) 819–836 H102_for TGGCGGGATCCTCCACAT
HERV-K_102 AF164610.1 (NCBI) 910–928 H102_rev CGTAAGGTGGGATGAGAGA
HERV-K_104 AF164612.1 (NCBI) 239–295 H104_for AGTCATCACCACTCCCTCATC
HERV-K_104 AF164612.1 (NCBI) 333–355 H104_rev GCCATATTTCAGACTATGAAACC
HERV-K_108 AF164614.1 (NCBI) 778–795 H108_for CACCCACAGATGATCAGT
HERV-K_108 AF164614.1 (NCBI) 908–925 H108_rev AAGGTGGGACGAGAGATT
HERV-K_113 AY037928.1 (NCBI) 565–582 H113_for TAGGGAAAAACCGCCTCA
HERV-K_113 AY037928.1 (NCBI) 694–711 H113_rev CGTGAACAAAGGTCTTGG
TBP CR456776.1 (NCBI) 11–29 TBP_for ACAACAGCCTGCCACCTTA
TBP CR456776.1 (NCBI) 111–130 TBP_rev GAATAGGCTGTGGGGTCAGT
Primer assays for expression analysis of AluYa5, AluYb8, H22q, HERVK17, HERV-K_11q23.3, HERV-K_22q11.21, LINE-1_5′, LINE-1_3′ and pyrosequencing assays for
H22q, HERVK17, LINE-1 were published previously (7).
by 45 amplification cycles consisting of denaturation at 95°C for
15 s, annealing for 20 s, and extension at 72°C for 45 s. Pyrose-
quencing was carried out on a PyroMark Q24 instrument (Qia-
gen) according to the manufacturer’s instruction. Corresponding
sequencing primers are listed in Table 2. Methylation values were
calculated as the mean value of 4 (LINE-1) or 6 (H22q;HERVK17 )
CpG sites, respectively.
STATISTICS
p Values were calculated by the Mann–Whitney U-test using SPSS
Statistics 20 (IBM) software. Correlation coefficients and their
respective level of significance were calculated by non-parametric
Spearman’s rank correlation coefficient (Spearman’s ρ) using SPSS
Statistics 20 (IBM) software.
RESULTS
LINE-1 DNA METHYLATION AND EXPRESSION IN UROTHELIAL CELL
CULTURES AND CELL LINES
LINE-1 promoter DNA methylation was assessed in a set of 10
primary urothelial cell cultures and 18 bladder cancer cell lines by
pyrosequencing of bisulfite-treated DNA using an assay described
previously (7). Briefly, the assay interrogates four CpG sites within
the internal promoter of approximately 400 full-length LINE-1
elements distributed across the genome. The bladder cancer cell
lines are all derived from urothelial carcinomas with the excep-
tion of SCaBER (squamous cell carcinoma of the urinary bladder)
and MGH-U4 (urothelial dysplasia). Additionally,bisulfite-treated
DNA from bladder cancer-associated fibroblasts, immortalized
urothelial cells (TERT-NHUC), and connective tissue originating
from a freshly dissected ureter were used for comparison.
While primary normal urothelial cell cultures exhibited the
high and homogenous LINE-1 promoter methylation expected
of normal cells, bladder cancer cell lines showed heterogeneous
changes, but with overall significantly decreased methylation lev-
els (Mann–Whitney U -test; p= 0.001) (Figure 1A). By grouping
bladder carcinoma cell lines into those either originating from
papillary (n= 7) or muscle-invasive (n= 9) cancers we found
those with muscle-invasive cancer origin displaying more sig-
nificant LINE-1 hypomethylation compared to cultured normal
urothelial cells (Mann–Whitney U -test; p< 0.001) (Figure 1A).
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Notably, the well-differentiated papillary cancer cell line BC61
showed the most prominent hypomethylation displaying only
14% mean LINE-1 promoter DNA methylation. Conversely, the
bladder papillary cell lines BFTC-905 and SW1710 retained high
methylation at LINE-1 promoters comparable with the levels
in normal urothelial cells (Figure 1A). Immortalized urothelial
cells (TERT-NHUC), uncultured epithelial cells and cells from
connective ureter tissue exhibited the same LINE-1 methylation
levels found in urothelial cell cultures, whereas cancer-associated
fibroblasts had comparably low methylation.
Expression analysis of LINE-1 elements was performed on a
set of 6 primary urothelial cell cultures and 18 bladder cancer cell
lines from different origins (7 papillary; 9 muscle-invasive, 2 oth-
ers) using two assays described previously (7) that detect either
unspliced, full-length LINE-1 transcripts (LINE-1_5 ′; ∼400 ele-
ments), or spliced and unspliced LINE-1 transcripts (LINE-1_3′;
∼2000 elements). TheLINE-1_3′-assay revealed decreased median
transcript levels in bladder cancer cells compared to cultured nor-
mal urothelial cells but the changes were overall not significant
(Figure 1B). In contrast, several cell lines showed increased expres-
sion by the LINE-1_5 ′-assay. Accordingly, we detected a prominent
shift toward unspliced, full-length LINE-1 transcripts in several
bladder cancer cell lines. The bladder cancer cell lines BC61, BFTC-
905, RT-112, UMUC6, SD, and VMCUB1 exhibited 2.0- to 4.2-fold
higher normalized LINE-1_5 ′ transcript levels compared to the
respective LINE-1_3′ mRNA levels. However, this shift was not
found across all cell lines and was therefore not overall significant.
Correlation analyses of the LINE-1 expression detected a robust
and significant positive correlation between the two assessed
LINE-1 transcript variants in bladder cancer cell lines (Spear-
man’s ρ= 0.628; p= 0.005). In bladder cancer cell lines, LINE-1
transcription correlated inversely with LINE-1 DNA methylation
without reaching the level of significance. Of note, inverse correla-
tion of LINE-1DNA methylation with expression measured by the
5′-assay (Spearman’s ρ= 0.443; p= 0.066) was substantially better
than that with the 3′-assay (Spearman’s ρ= 0.255; p= 0.307).
LINE-1 DNA METHYLATION AND EXPRESSION IN BENIGN AND
BLADDER CANCER TISSUES
To analyze LINE-1 promoter DNA methylation and LINE-1 tran-
script expression in benign and cancerous bladder tissues we
performed methylation and expression analyses using our estab-
lished pyrosequencing and quantitative RT-PCR assays on a set of
12 benign and 23 tumor probes and 11 benign and 24 cancer sam-
ples, respectively. Unfortunately, the DNA and RNA samples came
from different studies with only limited overlap. LINE-1 promoter
DNA methylation was highly significantly decreased in bladder
cancer specimen (Mann–Whitney U -test; p= 0.009) compared to
normal tissues with striking differences in their percent median
values (∆median= 8.5%) (Figure 1C). Like the decrease in DNA
methylation, LINE-1 expression changes were also similar in blad-
der tumor tissues to those found in cultured cells. The median
levels of transcripts assessed by the LINE-1_3′-assay tended to be
slightly higher in bladder cancer specimen, but the changes were
not significant (Mann–WhitneyU -test; p= 0.123) (Figure 1C). In
contrast, analyses of full-lengthLINE-1 transcripts using theLINE-
1_5 ′-assay revealed a significant increase of full-length transcript
levels in bladder tumor tissues (Mann–WhitneyU -test; p= 0.005)
(Figure 1C). Taken together, these changes resulted in a shift
toward full-length LINE-1 expression. Due to the limited overlap
of DNA and RNA samples the analysis of the correlation between
DNA methylation and expression was not possible.
AluYa5 AND AluYb8 EXPRESSION IN BENIGN AND BLADDER CANCER
SAMPLES
Additionally, we investigated the expression of the two most
commonly active retroelements of the AluY family (AluYa5 and
AluYb8) in our set of primary urothelial cell cultures and bladder
cancer cell lines. We found robust expression of both elements
in the primary urothelial cell cultures (Figure 2A). The expres-
sion of both elements tended to be diminished in cancer cell lines
of papillary origin and was slightly increased in cell lines from
muscle-invasive carcinomas without the difference reaching the
level of significance (Figure 2A). Of note, the expression of both
elements correlated strikingly throughout all samples (Spearman’s
ρ= 0.990; p< 0.001). By applying the same assays to our set of
benign and bladder cancer tissues we found no significant changes
in the expression of the AluYa5 retroelements. Instead, AluYb8
transcript levels were highly significantly increased in bladder can-
cer specimens (Mann–Whitney U -test; p< 0.001) (Figure 2B).
Other than in the cell lines, RNA levels of AluYb8 showed only
a weaker and non-significant correlation to AluYa5 expression in
the cancer tissues (Spearman’s ρ= 0.354; p= 0.090).
DNA METHYLATION OF HERV-K LTRs IN BENIGN AND BLADDER
CANCER PROBES
In order to investigate DNA methylation at HERV-K LTRs in
urothelial samples, we used two previously established pyrose-
quencing assays to analyze HERVK17 and H22q methylation in
bisulfite-converted DNA samples from the normal urothelial cell
cultures, bladder cancer cell lines, benign and bladder cancer tis-
sues also investigated for LINE-1 methylation. Intriguingly, we
found theHERVK17 LTR to be essentially demethylated in normal
urothelial cell cultures, but becoming hypermethylated in blad-
der cancer cells (Figure 3A). Noteworthy, DNA methylation levels
in the HERVK17 LTR remained low in most bladder cell lines
of papillary origin with no significant changes compared to cul-
tured urothelial cells (Mann–Whitney U -test; p= 0.635). Signif-
icantly elevated HERVK17 DNA methylation values were instead
regularly found in cancer cells derived from muscle-invasive blad-
der carcinomas (Mann–Whitney U -test; p< 0.001) (Figure 3A).
Interestingly,HERVK17 LTR methylation was considerably higher
in normal bladder tissues (median: 44.9%) compared to normal
urothelial cell cultures (median: 3.7%), remaining on the same
level in bladder cancer tissues (Figures 3A,C).
DNA methylation of the H22q proviral LTR was high in
benign bladder tissues (88.6%) and declined significantly in blad-
der cancer specimens (72.4%, Mann–Whitney U -test; p= 0.009)
(Figure 3C). Overall, LTR DNA methylation of both HERV-
K proviruses correlated well and highly significantly (Spear-
man’s ρ= 0.669; p< 0.001) in bladder cancer tissues. Although
overall comparable DNA methylation changes were found for
H22q and LINE-1 no correlation was detectable. Unexpectedly,
the H22q provirus was not hypomethylated, but significantly
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FIGURE 2 | Expression changes ofAluYa5 andAluYb8 in bladder
cancer. AluYa5 and AluYb8 RNA levels were measured by qRT-PCR in 6
normal urothelial cell cultures and 18 bladder cancer cell lines (A) as well
as in 11 benign and 24 bladder cancer samples (B). RNA levels were each
normalized to TBP and standardized to either the median RNA level of
normal urothelial cell cultures (A) or the median RNA level of benign
bladder tissues (B) set as 1. p Values calculated by the Mann–Whitney
U -test were given above the brackets for significant changes (p<0.05).
Missing p values demonstrate changes without reaching the level of
significance.
hypermethylated in bladder cancer cell lines compared to cul-
tured normal urothelial cells (Mann–Whitney U -test; p= 0.036)
(Figure 3B). Additionally, hypermethylation of the H22q LTR was
more prominent in papillary cancer cell lines.
DNA methylation of H22q LTR was slightly but significantly
lower in bladder cancer tissues originating from female patients
(Mann–Whitney U -test; p= 0.033) (Figure 3D). Conversely,
LTR methylation of the HERVK17 provirus was significantly
higher in female cancers (Mann–Whitney U -test; p= 0.033). In
contrast, LINE-1 promoter methylation showed no significant
gender-specific differences in cancers.
EXPRESSION ANALYSES OF DIFFERENT HERV-K PROVIRUSES
To assess HERV-K expression in benign and cancerous urothelial
samples we conducted qRT-PCR analyses on our set of nor-
mal urothelial cell cultures, bladder cancer cell lines, benign and
bladder tumor tissues. Initially, we performed expression analy-
ses of the four HERV-K retroelements which had previously been
investigated in prostate samples by our group (7). Then, we estab-
lished qRT-PCR assays for 14 additional HERV-K elements which
had been described as possibly expressed in bladder tissue by using
massively parallel signature sequencing (MPSS) (15). The strat-
egy for analysis of the expression of these HERV-K elements is
illustrated in Figure 4A. First, we performed standard end-point
PCR on our set of cultured normal urothelial and bladder cancer
cells. Transcriptionally active HERV-K elements were subjected
to quantitative RT-PCR using the same sample set. Those HERV-
K elements exhibiting detectable RNA levels in normal cultured
and urothelial cancer cells were analyzed for their expression in
benign and cancerous bladder tissues. We then conducted qRT-
PCR analyses on the eight HERV-K elements detectable in our set
of normal urothelial cell cultures and bladder cancer cell line.
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FIGURE 3 | DNA methylation changes in proviral HERVK17 and H22q
LTRs in bladder cancer. DNA methylation in the LTRs of HERVK17 (A) and
H22q (B) were analyzed by pyrosequencing in 10 normal urothelial cell
cultures and 18 bladder cancer cell lines. Additionally, HERVK17 and H22q
DNA methylation was assessed in immortalized urothelial cells
(TERT-NHUC) and in uncultured epithelial cells (uncultured UP) and
connective tissue from one ureter. (C) DNA methylation of HERVK17
(Continued)
FIGURE 3 | Continued
and H22q LTRs were each analyzed in a set of 12 benign and 23 cancerous
bladder tissues. (D) DNA methylation of HERVK17 and H22q LTRs from
tumor samples were each plotted against patients’ gender. Methylation is
plotted as mean methylation value from six CpGs each in percent. The high
standard deviation in some samples results from differences in the
methylation within the HERVK17 sequence, where the first three CpGs are
generally higher methylated as exemplified for data from J82, SW1710, and
647-V bladder cancer cell lines in the insert (A). p Values calculated by the
Mann–Whitney U -test are given above the brackets for significant changes
(p<0.05). Missing p values demonstrate changes without reaching the
level of significance.
In general, expression of these HERV-K elements was rather
low in these samples bordering on the limit of reliable quan-
tification (Figures 4B,C). Two of the analyzed HERV-K ele-
ments (HERVK17 and HERV-K102) showed significant expres-
sion changes between normal urothelial cell cultures and bladder
cancer cell lines. HERV-K102 was significantly downregulated
(Mann–Whitney U -test; p= 0.013) in bladder cancer cells inde-
pendent of the tumor type of origin, but expression was on
the limit of detection (Figure 4B). In general, expression of the
HERVK17 provirus was downregulated as well. In cultured nor-
mal urothelial cells its transcript level was low and these low
expression levels were preserved in most papillary carcinoma cell
lines (Figure 4B). Exceptionally, the RT4 cell line showed a high
increase of HERVK17 expression. Notably, all papillary cell lines
positive for HERVK17 expression (BC61, RT4, and UMUC6)
(Figure 4B) showed low methylation levels at the HERVK17
LTR comparable to those found in cultured normal urothelial
cells (Figure 3A). In cell lines originating from muscle-invasive
bladder carcinoma HERVK17 expression was essentially absent
(Figure 4B) fitting well with the hypermethylation found at the
HERVK17 locus in the respective cell lines (Figure 3A). Expres-
sion of the other HERV-K elements was low and no significant
expression changes were observed in bladder cancer cell lines
(Figure 4C).
In benign bladder samples expression of the HERVK17
provirus was low or absent with one exception showing sig-
nificant expression (Figure 4D). Likewise, most of the bladder
cancers exhibited low or absent expression of the HERVK17 locus,
whereas a few samples showed strikingly increased expression (up
to 700-fold). Across all samples, the expression of the HERVK17
provirus was not significantly changed (Mann–Whitney U -test;
p= 0.687). Expression levels of the other HERV-K retroele-
ments (HERV-K10, HERV-K_3q12.3, HERV-K_12q14.1, HERV-
K113) assessed in our bladder tissue set were rather low and no
significant expression increases were found in cancerous tissues
(Figure 4D).
DISCUSSION
In the present study we describe the impact of global methylation
changes in bladder cancers tissues and cell lines on the most impor-
tant classes of active retroelements in the human genome. With
respect to LINE-1 sequences, which make up 17% of the genome,
the quantitative methylation data obtained in this study confirm
previous finding of widespread hypomethylation in bladder can-
cers (9–11). Results of the DNA methylation analyses in bladder
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FIGURE 4 | Expression changes of proviral HERV-K elements in bladder
cancer. Expression of different HERV-K elements was assessed by end-point
PCR and qRT-PCR as indicated in (A). HERV-K RNA levels were measured by
qRT-PCR in 6 normal urothelial cell cultures and 18 bladder cancer cell lines
(B,C) and in a set of 11 benign and 24 cancerous bladder tissues (D). p Values
calculated by the Mann–Whitney U -test were given above the brackets for
significant changes (p<0.05). Missing p values demonstrate changes
without reaching the level of significance.
cancer cell lines revealed a tendency toward exacerbation in high-
grade and high-stage tumors, but also changes in cell lines from
papillary tumors. Evidently, LINE-1 hypomethylation is an early
and very frequent change in bladder cancer. Quantitative changes
of LINE-1 methylation were comparable to those in colorectal
cancers where LINE-1 hypomethylation also occurs early, but are
more pronounced compared to those in prostate cancer where
LINE-1 hypomethylation is a later event during carcinogenesis (7,
8, 22–24).
Nevertheless, the hypomethylation of the LINE-1 promoter
found in bladder cancer cell lines did not result in overall increased
LINE-1 expression, but went along with a shift toward full-length
LINE-1 expression as previously observed in prostate cancers
(7). A previous report has described the spliced form of LINE-1
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transcripts as the predominant isoform in normal prostate tis-
sue (25), which also seems to be the case in the urinary bladder.
In bladder cancer tissues the more prominent hypomethylation
compared to prostate cancer went along with a more general
increase in LINE-1 expression but only the expression of the full-
length LINE-1 isoform increased significantly. Notably, in bladder
cancer cell lines the correlation of LINE-1 promoter methylation
with the expression of the full-length transcript assessed by the
5′-assay was better than the correlation with the 3′-assay. Taken
together, the evidence suggests that the hypomethylation of the
LINE-1 promoter in cancers may contribute to a shift toward
full-length LINE-1 expression. The most obvious explanation for
that observation is that most LINE-1 transcripts in normal tis-
sues originate from truncated elements that represent parts of
longer transcripts from host gene promoters, whereas hypomethy-
lation in cancer may allow a degree of transcription initiation
from LINE-1 5′-internal promoters. In addition,LINE-1 promoter
DNA hypomethylation may enable expression from the LINE-1
antisense promoter (ASP) resulting in cancer-specific chimeric
transcripts (26). Noteworthy, DNA hypomethylation of a specific
LINE-1 element within the MET oncogene was recently shown to
enable expression of a chimeric L1-MET transcript starting from
the ASP in bladder cancers (10). As theLINE-1ASP is located in the
L1Hs 5′-UTR between nucleotides 400–600 (27), transcripts start-
ing from the ASP are detectable by our LINE-1_5′-assay. Hence,
elevated expression detected by the LINE-1_5′ assay may partially
reflect LINE-1 ASP activation.
Whereas TP53 mutations are relatively infrequent in prostate
carcinoma, in invasive bladder cancers TP53 missense mutations
are found in around 50% of the cases. Additional alterations of
“upstream” or “downstream” factors within the p53 network con-
tributing to p53 inhibition are common (28). Accordingly, the
more prominent impairment of LINE-1 expression in bladder can-
cers compared to prostate cancers may be partially explained by
p53 mediated regulation of LINE-1 expression (29, 30).
Notably, only full-length LINE-1 transcripts contain informa-
tion for both LINE-1 open reading frames (ORF1 and ORF2)
required for retrotransposition of LINE-1 (31, 32) and other non-
autonomous retroelements like SINEs and processed pseudogenes.
Up to now roughly 100 disease-causing retrotransposition events,
usually occurring during early embryonic or germ line develop-
ment, are known, predominantly elicited by retrotransposed AluY
elements (33). Additionally,within the last few years several reports
described examples of LINE-1 retrotransposition in different can-
cers (34–37). Analyses for bladder cancers are still missing, but
will presumably be enabled soon by the data from an ongoing
whole-genome sequencing project.
Surprisingly, in contrast to the hypomethylation observed at
the LINE-1 promoter in bladder cancer cell lines as compared to
normal urothelial cells the LTRs of HERVK17 and H22q showed
overall significantly increased methylation levels. Nevertheless,
expression of the H22q provirus remained undetectable in any
tumor. This is in good accordance to the study by Stauffer et
al. (15). Here, H22q expression was not detectable by MPSS
in bladder, but only in prostate samples. Predominant prosta-
tic expression of this provirus was confirmed by others (7, 12,
13). In contrast, antibodies reacting with H22q Gag protein were
found in the sera from bladder cancer patients (12). As in the same
studyH22q mRNA was not found in bladder carcinoma specimen,
the positive antibody reaction may be due to cross-reactivity of a
serum antibody to a different protein resembling the H22q Gag.
HERVK17 showed expression only in bladder cancer cell lines of
papillary origin whereas expression of the provirus was nearly
absent in muscle-invasive cell lines. Noteworthy, expression was
only detectable in cell lines with low HERVK17 methylation sug-
gesting that DNA methylation may constitute one factor limiting
its expression.
Many studies published in the last decade emphasize the
strongly tissue- and cancer-specific expression pattern of HERV-K
elements (7, 12, 38–41). The mechanisms underlying this pat-
tern are still poorly understood, although tissue-specific tran-
scription factors and epigenetic regulation are clearly implicated.
In our present study expression of eight specific HERV-K s was
detectable in urothelial cells by end-point PCR, whereas that
of nine others was not. Quantification of these HERV-K tran-
script levels revealed generally low expression in normal bladder
which is in good concordance to previously published results
assessed by MPSS (15). Among the faintly expressed elements
was the HERV-K113 provirus. Its expression in nearly all blad-
der samples does not fit with previous observations that HERV-
K113 occurs in a small part of the human population. HERV-
K113 was likely acquired in Africa during or after the migration
by Homo sapiens north and eastward and showed the high-
est frequencies in individuals from central Africa (∼20–30%)
(42, 43). A large study assessing more than 2800 individu-
als in the UK found HERV-K113 allele frequency of approxi-
mately 7% (44). Most likely, the weak HERV-K113 expression
in our data was at least partially caused by cross-reactivity of
the used assay with another very closely related HERV-K ele-
ment. Except for HERV-K102 and HERVK17 (as discussed above)
significant cancer-specific expression changes of these elements
were detectable neither in bladder cancer cell lines nor tis-
sues. Transcripts of the proviruses HERV-K_11q23.3 and HERV-
K_22q11.21 are strongly expressed in testicular cancers (38) but
not in prostate tissues (7). Of these, only HERV-K_22q11.21
showed detectable expression in bladder tissues underlining
again the strongly tissue-specific expression of distinct HERV-K
elements.
In contrast to the methylation changes in bladder cancer cell
lines HERVK17 LTR methylation was decreased in bladder tumor
tissues with a good correlation to H22q methylation changes. Puz-
zlingly, HERVK17 LTR exhibited significant higher methylation
in normal bladder tissues compared to cultured urothelial cells.
In order to exclude that the LTR becomes demethylated during
culture, we analyzed freshly prepared, uncultured urothelial cells,
which showed only slightly higher methylation than the cultured
cells. In addition, residual connective tissue from a ureter after
removal of the epithelial layer also exhibited lower HERK17 DNA
methylation than benign bladder tissues. Instead, the HERVK17
mean methylation value in benign bladder tissue is rather com-
parable to that found in benign prostate tissues [mean= 35.1 vs.
44.9%; (7)]. The difference toward cultured cells could therefore
result from an admixture of other cell types, such as infiltrating
immune cells that are prominent in cancer-carrying bladders or
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may reflect one of the few distinctive differences between ureter
and bladder urothelium tissue (45).
DNA methylation of both HERV-K LTRs but not of the LINE-
1 promoter showed significant correlation to patient gender. One
explanation for these differences may be the well-known influence
of androgens on the development of bladder cancer (46). The cor-
relation could also result from a higher fraction of smokers in the
male population. Smoking is a main risk factor for urothelial can-
cers accounting partly for its higher incidence in males (47). As
smoking induces several epigenetic changes in urothelial cells (48)
it may also affect HERV methylation and contribute to aberrant
HERV expression. Additionally, HERVs were reported to become
induced by smoking in urothelial cell lines and tissues (49) which
may be causative for HERVK17 expression in a few cancer tissues.
As the smoking status was not consistently assessed in our patient
cohort we cannot confirm these assumptions.
To unravel the puzzle of the regulation of specific HERV ele-
ments high-throughput transcript analyses of HERV expression
are highly desirable. Likewise, detailed studies are needed to inves-
tigate the tissues-specific regulators of HERV expression as pub-
lished by us and others (7, 50–53). In this respect, the present study
provides a framework for studies on urothelial tissue.
Expression of AluYa5 and AluYb8 SINEs was not significantly
altered in bladder cancer cell lines. In contrast, in bladder cancer
tissues AluYb8 but not AluYa5 expression was highly significantly
elevated. It is generally assumed that Alu induction is related
to several different kinds of cellular stresses (54). Human Alu
and rodent B2 SINE are activated in response to heat shock (55,
56) and are consecutively involved in heat shock-related stress
response (57). Alu expression was elevated during hypoxic stress
in human glioblastoma cells, whereas tRNA genes and B2 elements
were inhibited in response to hypoxia in rat cardiomyocytes, even
though tRNA genes and SINEs have very similar promoters (58,
59). As standardized cell culture conditions are unlikely to induce
heat shock or hypoxic stresses, it is plausible to assume that only
basal level of Alu transcription were observed in cultured cells.
In bladder cancer tissues, a likely inducer of AluYb8 expression
is hypoxic stress as hypoxia is a well-known feature in this solid
tumor (60). In contrast,AluYa5 expression was only slightly altered
and may not respond to this kind of cellular stress. The factors
regulating SINE expression in stressed cells and the reasons why
these factors do not affect the transcription of other small RNAs
with comparable promoters are largely unknown (54). Moreover,
our data hint at an element-specific regulation of Alu expression
in response to cellular stresses. Alu elements are characterized by
their huge number with limited diversity (61), which complicates
methylation analyses and calls for genome-wide high-throughput
approaches. Recently, such global sequencing approaches for Alu
methylation analyses have revealed tissue-specific methylation of
certain Alu elements (62) and a decline of Alu DNA methyla-
tion in several cancers which was most pronounced for members
of the AluY family (63–66). In benign tissues the methylation
level of specific Alu elements and the degree of their methylation
heterogeneity is dependent on their genomic location and their
adjacent sequence motifs and heterogeneity increases in cancer tis-
sues (67). Interestingly, recent whole-genome sequencing studies
suggest that besides LINE-1, retrotranspositions in human cancers
substantially involve Alu elements (35). In that respect, our study
invites the speculation that LINE-1 activation in bladder cancers
may also facilitate AluYb8 retrotransposition in particular.
In summary, our study provides the first survey of expression
and methylation of the most active retroelement classes in bladder
cancer. Even though changes in LINE-1 methylation and expres-
sion are more pronounced in this cancer type than those observed
in our previous study on prostate cancer (7), the results further
support our conclusion that apparently global DNA hypomethy-
lation affects retroelements to very different extents and does not
lead to wholesale reexpression. Rather, changes in methylation
and expression may have to be investigated at many individual
elements to identify those that contribute to genomic instability
and deregulation of gene expression in each cancer type.
ACKNOWLEDGMENTS
We are grateful to Prof. Rainer Engers for histopathological
assessment of tissue samples and to Christiane Hader for exper-
imental support. The project was funded by a grant from the
Deutsche Forschungsgemeinschaft (DFG; Schu604/16-3) and the
Reinhard-Nagel-Foundation.
REFERENCES
1. Shen H, Laird PW. Interplay
between the cancer genome and
epigenome. Cell (2013) 153:38–55.
doi:10.1016/j.cell.2013.03.008
2. Jones PA, Baylin SB. The epige-
nomics of cancer. Cell (2007)
128:683–92. doi:10.1016/j.cell.2007.
01.029
3. Hoffmann MJ, Schulz WA.
Causes and consequences of
DNA hypomethylation in human
cancer. Biochem Cell Biol (2005)
83:296–321. doi:10.1139/o05-036
4. Wilson AS, Power BE, Molloy
PL. DNA hypomethylation and
human diseases. Biochim Biophys
Acta (2007) 1775:138–62.
5. Goodier JL, Kazazian HH Jr. Retro-
transposons revisited: the restraint
and rehabilitation of parasites. Cell
(2008) 135:23–35. doi:10.1016/j.
cell.2008.09.022
6. Schulz WA. L1 retrotransposons in
human cancers. J Biomed Biotech-
nol (2006) 2006:83672. doi:10.1155/
JBB/2006/83672
7. Goering W, Ribarska T, Schulz
WA. Selective changes of
retroelement expression in
human prostate cancer. Car-
cinogenesis (2011) 32:1484–92.
doi:10.1093/carcin/bgr181
8. Florl AR, Steinhoff C, Muller M,
Seifert HH, Hader C, Engers R,
et al. Coordinate hypermethylation
at specific genes in prostate carci-
noma precedes LINE-1 hypomethy-
lation. Br J Cancer (2004) 91:
985–94.
9. Florl AR, Lower R, Schmitz-Drager
BJ, Schulz WA. DNA methylation
and expression of LINE-1 and
HERV-K provirus sequences in
urothelial and renal cell carci-
nomas. Br J Cancer (1999) 80:
1312–21. doi:10.1038/sj.bjc.
6690524
10. Wolff EM, Byun HM, Han HF,
Sharma S, Nichols PW, Siegmund
KD, et al. Hypomethylation of a
LINE-1 promoter activates an alter-
nate transcript of the MET onco-
gene in bladders with cancer. PLoS
Genet (2010) 6:e1000917. doi:10.
1371/journal.pgen.1000917
11. van Bemmel D, Lenz P, Liao LM,
Baris D, Sternberg LR, Warner A, et
al. Correlation of LINE-1 methyla-
tion levels in patient-matched buffy
coat, serum, buccal cell, and bladder
tumor tissue DNA samples. Cancer
Epidemiol Biomarkers Prev (2012)
21:1143–8. doi:10.1158/1055-9965.
EPI-11-1030
12. Ishida T, Obata Y, Ohara N, Mat-
sushita H, Sato S, Uenaka A, et al.
Identification of the HERV-K gag
antigen in prostate cancer by SEREX
using autologous patient serum and
its immunogenicity. Cancer Immun
(2008) 8:15.
13. Tomlins SA, Laxman B,
Dhanasekaran SM, Helgeson
BE, Cao X, Morris DS, et al.
Distinct classes of chromosomal
rearrangements create oncogenic
ETS gene fusions in prostate
cancer. Nature (2007) 448:595–9.
doi:10.1038/nature06024
Frontiers in Oncology | Molecular and Cellular Oncology September 2013 | Volume 3 | Article 255 | 10
Kreimer et al. Retroelements in bladder cancer
14. Hermans KG, Van Der Korput HA,
Van Marion R,Van De Wijngaart DJ,
Ziel-Van Der Made A, Dits NF, et
al. Truncated ETV1, fused to novel
tissue-specific genes, and full-length
ETV1 in prostate cancer. Cancer
Res (2008) 68:7541–9. doi:10.1158/
0008-5472.CAN-07-5930
15. Stauffer Y, Theiler G, Sperisen P,
Lebedev Y, Jongeneel CV. Digi-
tal expression profiles of human
endogenous retroviral families in
normal and cancerous tissues. Can-
cer Immun (2004) 4:2.
16. Schiavetti F, Thonnard J, Colau
D, Boon T, Coulie PG. A human
endogenous retroviral sequence
encoding an antigen recognized on
melanoma by cytolytic T lympho-
cytes. Cancer Res (2002) 62:5510–6.
17. Koch A, Hatina J, Rieder H, Seifert
HH, Huckenbeck W, Jankowiak F,
et al. Discovery of TP53 splice vari-
ants in two novel papillary urothe-
lial cancer cell lines. Cell Oncol
(Dordr) (2012) 35:243–57. doi:10.
1007/s13402-012-0082-8
18. Chapman EJ, Williams SV, Platt FM,
Hurst CD, Chambers P, Roberts
P, et al. Integrated genomic and
transcriptional analysis of the
in vitro evolution of telomerase-
immortalized urothelial cells
(TERT-NHUC). Genes Chromo-
somes Cancer (2009) 48:694–710.
doi:10.1002/gcc.20672
19. Seifert HH, Meyer A, Cronauer MV,
Hatina J, Muller M, Rieder H, et al.
A new and reliable culture system
for superficial low-grade urothelial
carcinoma of the bladder. World
J Urol (2007) 25:297–302. doi:10.
1007/s00345-007-0166-7
20. Swiatkowski S, Seifert HH, Steinhoff
C, Prior A, Thievessen I, Schliess F,
et al. Activities of MAP-kinase path-
ways in normal uroepithelial cells
and urothelial carcinoma cell lines.
Exp Cell Res (2003) 282:48–57. doi:
10.1006/excr.2002.5647
21. Pfaffl MW. A new mathematical
model for relative quantification in
real-time RT-PCR. Nucleic Acids Res
(2001) 29:e45. doi:10.1093/nar/29.
9.e45
22. Ogino S, Nosho K, Kirkner GJ,
Kawasaki T, Chan AT, Schernham-
mer ES, et al. A cohort study of
tumoral LINE-1 hypomethylation
and prognosis in colon cancer. J
Natl Cancer Inst (2008) 100:1734–8.
doi:10.1093/jnci/djn359
23. Yegnasubramanian S, Haffner MC,
Zhang Y, Gurel B, Cornish TC,
Wu Z, et al. DNA hypomethyla-
tion arises later in prostate can-
cer progression than CpG island
hypermethylation and contributes
to metastatic tumor heterogeneity.
Cancer Res (2008) 68:8954–67. doi:
10.1158/0008-5472.CAN-07-6088
24. Baba Y, Huttenhower C, Nosho K,
Tanaka N, Shima K, Hazra A, et al.
Epigenomic diversity of colorectal
cancer indicated by LINE-1 methy-
lation in a database of 869 tumors.
Mol Cancer (2010) 9:125. doi:10.
1186/1476-4598-9-125
25. Belancio VP, Roy-Engel AM,
Pochampally RR, Deininger P.
Somatic expression of LINE-1
elements in human tissues. Nucleic
Acids Res (2010) 38:3909–22.
doi:10.1093/nar/gkq132
26. Cruickshanks HA, Tufarelli
C. Isolation of cancer-specific
chimeric transcripts induced
by hypomethylation of the
LINE-1 antisense promoter.
Genomics (2009) 94:397–406.
doi:10.1016/j.ygeno.2009.08.013
27. Speek M. Antisense promoter of
human L1 retrotransposon dri-
ves transcription of adjacent cel-
lular genes. Mol Cell Biol (2001)
21:1973–85. doi:10.1128/MCB.21.
6.1973-1985.2001
28. Schulz WA. Understanding urothe-
lial carcinoma through cancer
pathways. Int J Cancer (2006)
119:1513–8. doi:10.1002/ijc.21852
29. Haoudi A, Semmes OJ, Mason JM,
Cannon RE. Retrotransposition-
competent human LINE-1 induces
apoptosis in cancer cells with
intact p53. J Biomed Biotechnol
(2004) 2004:185–94. doi:10.1155/
S1110724304403131
30. Harris CR, Dewan A, Zupnick A,
Normart R, Gabriel A, Prives C, et al.
p53 responsive elements in human
retrotransposons. Oncogene (2009)
28:3857–65. doi:10.1038/onc.2009.
246
31. Moran JV, Holmes SE, Naas TP,
Deberardinis RJ, Boeke JD, Kazazian
HH Jr. High frequency retrotrans-
position in cultured mammalian
cells. Cell (1996) 87:917–27. doi:10.
1016/S0092-8674(00)81998-4
32. Evans JD, Peddigari S, Chaurasiya
KR, Williams MC, Martin SL.
Paired mutations abolish and
restore the balanced anneal-
ing and melting activities of
ORF1p that are required for
LINE-1 retrotransposition. Nucleic
Acids Res (2011) 39:5611–21.
doi:10.1093/nar/gkr171
33. Hancks DC, Kazazian HH Jr. Active
human retrotransposons: variation
and disease. Curr Opin Genet Dev
(2012) 22:191–203. doi:10.1016/j.
gde.2012.02.006
34. Iskow RC, McCabe MT, Mills RE,
Torene S, Pittard WS, Neuwald AF,
et al. Natural mutagenesis of human
genomes by endogenous retrotrans-
posons. Cell (2010) 141:1253–61.
doi:10.1016/j.cell.2010.05.020
35. Lee E, Iskow R, Yang L, Gokcu-
men O, Haseley P, Luquette LJ III,
et al. Landscape of somatic retro-
transposition in human cancers.
Science (2012) 337:967–71. doi:10.
1126/science.1222077
36. Solyom S, Ewing AD, Hancks DC,
Takeshima Y, Awano H, Matsuo
M, et al. Pathogenic orphan trans-
duction created by a nonrefer-
ence LINE-1 retrotransposon. Hum
Mutat (2012) 33:369–71. doi:10.
1002/humu.21663
37. Shukla R, Upton KR, Munoz-Lopez
M, Gerhardt DJ, Fisher ME, Nguyen
T, et al. Endogenous retrotranspo-
sition activates oncogenic pathways
in hepatocellular carcinoma. Cell
(2013) 153:101–11. doi:10.1016/j.
cell.2013.02.032
38. Flockerzi A, Ruggieri A, Frank
O, Sauter M, Maldener E, Kop-
per B, et al. Expression patterns
of transcribed human endogenous
retrovirus HERV-K(HML-2) loci in
human tissues and the need for
a HERV Transcriptome Project.
BMC Genomics (2008) 9:354. doi:
10.1186/1471-2164-9-354
39. Wang-Johanning F, Radvanyi
L, Rycaj K, Plummer JB, Yan
P, Sastry KJ, et al. Human
endogenous retrovirus K trig-
gers an antigen-specific immune
response in breast cancer patients.
Cancer Res (2008) 68:5869–77.
doi:10.1158/0008-5472.CAN-07-
6838
40. Nellaker C, Li F, Uhrzander F,
Tyrcha J, Karlsson H. Expression
profiling of repetitive elements by
melting temperature analysis: vari-
ation in HERV-W gag expression
across human individuals and tis-
sues. BMCGenomics (2009) 10:532.
doi:10.1186/1471-2164-10-532
41. Wang-Johanning F, Rycaj K,
Plummer JB, Li M, Yin B, Frerich
K, et al. Immunotherapeutic
potential of anti-human endoge-
nous retrovirus-K envelope
protein antibodies in targeting
breast tumors. J Natl Can-
cer Inst (2012) 104:189–210.
doi:10.1093/jnci/djr540
42. Turner G, Barbulescu M, Su M,
Jensen-Seaman MI, Kidd KK, Lenz
J. Insertional polymorphisms of
full-length endogenous retroviruses
in humans. Curr Biol (2001)
11:1531–5. doi:10.1016/S0960-
9822(01)00455-9
43. Moyes DL, Martin A, Sawcer S, Tem-
perton N, Worthington J, Griffiths
DJ, et al. The distribution of
the endogenous retroviruses HERV-
K113 and HERV-K115 in health
and disease. Genomics (2005) 86:
337–41. doi:10.1016/j.ygeno.2005.
06.004
44. Moyes DL, Goris A, Ban M, Comp-
ston A, Griffiths DJ, Sawcer S, et
al. HERV-K113 is not associated
with multiple sclerosis in a large
family-based study. AIDS Res Hum
Retroviruses (2008) 24:363–5. doi:
10.1089/aid.2007.0196
45. Catto JW, Yates DR, Rehman I,
Azzouzi AR, Patterson J, Sibony
M, et al. Behavior of urothelial
carcinoma with respect to anatom-
ical location. J Urol (2007) 177:
1715–20. doi:10.1016/j.juro.2007.
01.030
46. Waliszewski P, Waliszewska MK,
Hemstreet GP III, Hurst RE.
Expression of sex steroid receptor
genes and comodulation with
retinoid signaling in normal
human uroepithelial cells and
bladder cancer cell lines. Urol Oncol
(1997) 3:141–7. doi:10.1016/S1078-
1439(98)00011-8
47. Kiriluk KJ, Prasad SM, Patel AR,
Steinberg GD, Smith ND. Blad-
der cancer risk from occupational
and environmental exposures. Urol
Oncol (2012) 30:199–211. doi:10.
1016/j.urolonc.2011.10.010
48. Brait M, Munari E, Lebron
C, Noordhuis MG, Begum S,
Michailidi C, et al. Genome-wide
methylation profiling and the
PI3K-AKT pathway analysis asso-
ciated with smoking in urothelial
cell carcinoma. Cell Cycle (2013)
12:1058–70. doi:10.4161/cc.24050
49. Gabriel U, Steidler A, Trojan L,
Michel MS, Seifarth W, Fabarius
A. Smoking increases transcription
of human endogenous retroviruses
in a newly established in vitro
cell model and in normal urothe-
lium. AIDS Res Hum Retroviruses
(2010) 26:883–8. doi:10.1089/aid.
2010.0014
50. Christensen T. HERVs in neu-
ropathogenesis. J Neuroimmune
Pharmacol (2010) 5:326–35. doi:10.
1007/s11481-010-9214-y
51. Fuchs NV, Kraft M, Tondera C, Han-
schmann KM, Lower J, Lower R.
Expression of the human endoge-
nous retrovirus (HERV) group
HML-2/HERV-K does not depend
on canonical promoter elements
but is regulated by transcrip-
tion factors Sp1 and Sp3. J Virol
(2011) 85:3436–48. doi:10.1128/
JVI.02539-10
52. Katoh I, Mirova A, Kurata S,
Murakami Y, Horikawa K, Nakakuki
www.frontiersin.org September 2013 | Volume 3 | Article 255 | 11
Kreimer et al. Retroelements in bladder cancer
N, et al. Activation of the long ter-
minal repeat of human endogenous
retrovirus K by melanoma-specific
transcription factor MITF-M. Neo-
plasia (2011) 13:1081–92.
53. Gonzalez-Hernandez MJ, Swan-
son MD, Contreras-Galindo R,
Cookinham S, King SR, Noel RJ
Jr, et al. Expression of human
endogenous retrovirus type K
(HML-2) is activated by the Tat
protein of HIV-1. J Virol (2012)
86:7790–805. doi:10.1128/JVI.
07215-11
54. Nikitina TV, Tischenko LI, Schulz
WA. Recent insights into regula-
tion of transcription by RNA poly-
merase III and the cellular functions
of its transcripts. Biol Chem (2011)
392:395–404. doi:10.1515/BC.2011.
049
55. Fornace AJ Jr, Mitchell JB. Induc-
tion of B2 RNA polymerase III tran-
scription by heat shock: enrichment
for heat shock induced sequences
in rodent cells by hybridiza-
tion subtraction. Nucleic Acids Res
(1986) 14:5793–811. doi:10.1093/
nar/14.14.5793
56. Li TH, Schmid CW. Differen-
tial stress induction of individ-
ual Alu loci: implications for tran-
scription and retrotransposition.
Gene (2001) 276:135–41. doi:10.
1016/S0378-1119(01)00637-0
57. Mariner PD, Walters RD, Espinoza
CA, Drullinger LF, Wagner SD,
Kugel JF, et al. Human Alu RNA
is a modular transacting repressor
of mRNA transcription during heat
shock. Mol Cell (2008) 29:499–509.
doi:10.1016/j.molcel.2007.12.013
58. Ernens I, Goodfellow SJ, Innes F,
Kenneth NS, Derblay LE, White
RJ, et al. Hypoxic stress suppresses
RNA polymerase III recruitment
and tRNA gene transcription in
cardiomyocytes. Nucleic Acids Res
(2006) 34:286–94. doi:10.1093/nar/
gkj402
59. Pal A, Srivastava T, Sharma MK,
Mehndiratta M, Das P, Sinha S,
et al. Aberrant methylation and
associated transcriptional mobiliza-
tion of Alu elements contributes to
genomic instability in hypoxia. JCell
MolMed (2010) 14:2646–54. doi:10.
1111/j.1582-4934.2009.00792.x
60. Ord JJ, Streeter EH, Roberts IS,
Cranston D, Harris AL. Comparison
of hypoxia transcriptome in vitro
with in vivo gene expression in
human bladder cancer. Br J Can-
cer (2005) 93:346–54. doi:10.1038/
sj.bjc.6602666
61. Batzer MA, Deininger PL. Alu
repeats and human genomic diver-
sity. Nat Rev Genet (2002) 3:370–9.
doi:10.1038/nrg798
62. Xie H, Wang M, Bonaldo Mde
F, Smith C, Rajaram V, Gold-
man S, et al. High-throughput
sequence-based epigenomic
analysis of Alu repeats in
human cerebellum. Nucleic
Acids Res (2009) 37:4331–40.
doi:10.1093/nar/gkp393
63. Daskalos A, Nikolaidis G, Xinar-
ianos G, Savvari P, Cassidy A,
Zakopoulou R, et al. Hypomethyla-
tion of retrotransposable elements
correlates with genomic instability
in non-small cell lung cancer. Int
J Cancer (2009) 124:81–7. doi:10.
1002/ijc.23849
64. Szpakowski S, Sun X, Lage JM,
Dyer A, Rubinstein J, Kowal-
ski D, et al. Loss of epige-
netic silencing in tumors pref-
erentially affects primate-specific
retroelements. Gene (2009) 448:
151–67. doi:10.1016/j.gene.2009.08.
006
65. Cho YH, Yazici H, Wu HC, Terry
MB, Gonzalez K, Qu M, et al.
Aberrant promoter hypermethyla-
tion and genomic hypomethyla-
tion in tumor, adjacent normal tis-
sues and blood from breast can-
cer patients. Anticancer Res (2010)
30:2489–96.
66. Xiang S, Liu Z, Zhang B, Zhou J, Zhu
BD, Ji J, et al. Methylation status of
individual CpG sites within Alu ele-
ments in the human genome and
Alu hypomethylation in gastric car-
cinomas.BMCCancer (2010) 10:44.
doi:10.1186/1471-2407-10-44
67. Xie H, Wang M, De Andrade A,
Bonaldo Mde F, Galat V, Arndt
K, et al. Genome-wide quantitative
assessment of variation in DNA
methylation patterns. Nucleic Acids
Res (2011) 39:4099–108. doi:10.
1093/nar/gkr017
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or financial relationships that
could be construed as a potential con-
flict of interest.
Received: 24 June 2013; paper pending
published: 01 August 2013; accepted: 11
September 2013; published online: 26
September 2013.
Citation: Kreimer U, Schulz WA, Koch
A, Niegisch G and Goering W (2013)
HERV-K and LINE-1 DNA methy-
lation and reexpression in urothelial
carcinoma. Front. Oncol. 3:255. doi:
10.3389/fonc.2013.00255
This article was submitted to Molecular
and Cellular Oncology, a section of the
journal Frontiers in Oncology.
Copyright© 2013Kreimer, Schulz, Koch,
Niegisch and Goering . This is an open-
access article distributed under the terms
of the Creative Commons Attribution
License (CC BY). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) or licensor
are credited and that the original publica-
tion in this journal is cited, in accordance
with accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Oncology | Molecular and Cellular Oncology September 2013 | Volume 3 | Article 255 | 12
